Vytorin Data Showing Superiority Over Lipitor Added To Labeling
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck/Schering-Plough’s labeling update for Vytorin includes results of the VYVA study.
You may also be interested in...
Vytorin Label Adds Superiority Data Over Crestor
FDA approved the inclusion of new data on the cholesterol-lowering efficacy of the ezetimibe/simvastatin fixed-dose combination.
Vytorin Label Adds Superiority Data Over Crestor
FDA approved the inclusion of new data on the cholesterol-lowering efficacy of the ezetimibe/simvastatin fixed-dose combination.
Vytorin Outpaces Crestor In Comparison Study
Schering-Plough/Merck’s ezetimibe/simvastatin combination shows better LDL cholesterol reduction than Crestor.